Aclacinomycin A, A2601
Topoisomerase I and II inhibitor
Brivanib (BMS-540215), A2597
(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
Brivanib (BMS-540215), A2597
(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
(-)-Epigallocatechin gallate (EGCG), A2600
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
(-)-Epigallocatechin gallate (EGCG), A2600
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
PMSF, A2587
phenylmethanesulfonyl fluoride
PMSF, A2587
phenylmethanesulfonyl fluoride
PPACK Dihydrochloride, A2588
N-(2-amino-3-phenylpropanoyl)-1-[1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide
PPACK Dihydrochloride, A2588
N-(2-amino-3-phenylpropanoyl)-1-[1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide
Nafamostat Mesylate(FUT-175), A2586
(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid
